Blade Therapeutics Announces FDA Orphan Drug Designation Granted to Cudetaxestat for Treatment of Systemic Sclerosis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #Blade--Blade Therapeutics, Inc. announces that FDA has granted orphan drug designation for cudetaxestat for potential treatment of systemic sclerosis (SSc).

Click to view original post